Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques.
Direct evidence for persistence of Mycobacterium tuberculosis (Mtb) during asymptomatic latent TB infection (LTBI) in humans is currently lacking. Moreover, while a 12-week regimen of once-weekly isoniazid and rifapentine (3HP) is currently recommended by the U.S. Centers for Disease Control and Prevention (CDC) as treatment for LTBI, experimental evidence for 3HP-mediated clearance of persistent Mtb infection in human lungs has not been established. Using a nonhuman primate (NHP) model of tuberculosis, we sought to assess 3HP treatment-mediated clearance of Mtb infection in latently infected macaques. Sixteen NHPs were infected via inhalation with ~10 CFU of Mtb CDC1551, after which asymptomatic animals were either treated with 3HP or left untreated. Pharmacokinetics of the 3HP regimen were measured. Following treatment, animals were co-infected with Simian Immunodeficiency Virus (SIV) to assess reactivation of LTBI and development of active TB disease (ATB). Fourteen NHPs remained free of clinical signs or microbiological evidence of active TB following infection with Mtb and were subsequently either treated with 3HP (n=7) or left untreated (n=7). Untreated NHPs were asymptomatic for 7 months but harbored persistent Mtb infection as evidenced by reactivation of latent infection following SIV co-infection. However, none of the treated animals developed TB reactivation disease and remained without clinical or microbiological evidence of persistent bacilli, suggesting treatment-mediated clearance of bacteria. Mtb can persist in asymptomatic macaques for at least 7 months. Furthermore, 3HP treatment effectively cleared bacteria and prevented reactivation of TB in latently-infected macaques.